Email this article Evaluation of Podocalyxin level in pre-eclampsia with severe features' patients: a cross-sectional study
Abstract
Background: This study aims to evaluate the level of podocalyxin (PCX) in preeclampsia with severe features patients and correlate it with the results of laboratory tests.
Methods: The current study was a cross-sectional study conducted in Assiut Women Health Hospital between April and October 2018. The study included 60 patients divided into two groups; Group (A): 30 patients diagnosed to have preeclampsia with severe features and Group (B): 30 patients as normal control group. Complete laboratory investigations with measurements of the PCX level was performed for all study participants.
Results: No statistically significant difference between the study group and control group according to blood urea (p= 0.339) and serum creatinine (p= 0.801).There was statistically significant difference between the study group and control group according to PCX level (p= 0.001); the mean PCX was 3340.0 ± 2394.6 in the study group versus 1083.5±1400.2 in the control group. Univariate analysis revealed podocalyxin was not correlated with clinical data or laboratory investigations.
Conclusions: Podocalyxin levels were significantly elevated in preeclampsia.
Keywords
Full Text:
PDFReferences
Lai C, Coulter SA, Woodruff A. Hypertension and Pregnancy. Tex Heart Inst J. 2017;44(5):350-1.
Duhig KE, Shennan AH. Recent advances in the diagnosis and management of pre-eclampsia. F1000 Prime Rep. 2015;7:24.
Prakash J, Ganiger VC. Acute Kidney Injury in Pregnancy-specific Disorders. Indian J Nephrol. 2017;27(4):258-70.
Palacios de Franco Y, Velazquez K, Segovia N. Urinary podocalyxin as a marker of preeclampsia in a Hispanic population. Int J Physiol Pathophysiol Pharmacol. 2014;6(2):115-24.
Asao R, Asanuma K, Kodama F. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 2012;7(9):1385-93.
Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int. 2014;86(2):275-85.
Chen Q, Wang Y, Li Y, Zhao M, Nie G. Serum podocalyxin is significantly increased in early-onset preeclampsia and may represent a novel marker of maternal endothelial cell dysfunction. J Hypertens. 2017;35(11):2287-94.
Wang Y, Zhao S, Loyd S, Groome LJ. Increased urinary excretion of nephrin, podocalyxin, and βig-h3 in women with preeclampsia. Am J Physiol Renal Physiol. 2012;302(9):F1084-9.
Krutzén E, Olofsson P, Bäck SE, Nilsson-Ehle P. Glomerular filtration rate in pregnancy: a study in normal subjects and in patients with hypertension, preeclampsia and diabetes. Scand J Clin Lab Invest. 1992;52(5):387-92.
Hara M, Yamagata K, Tomino Y. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 2012;55(11):2913-9.
Roberts JM, Bodnar LM, Lain KY, Hubel CA, Markovic N, Ness RB, Powers RW. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension. 2005;46:1263-9.
Vyakaranam S, Bhongir A, Patlolla D, Chintapally R. Study of serum uric acid and creatinine in hypertensive disorders of pregnancy. International Journal of Medical Science and Public Health. 2015;4(10):1424-8.
